Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
Orrin M. Troum,M D
mi
from
Santa Monica, CA
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
Orrin M. Troum,M D
mi
from
Santa Monica, CA
Click here to add this to my saved trials
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
G. Timothy Kelly, MD
mi
from
Las Vegas, NV
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
G. Timothy Kelly, MD
mi
from
Las Vegas, NV
Click here to add this to my saved trials
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
Health Research of Oklahoma
mi
from
Oklahoma City, OK
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
Health Research of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
Arthritis Group
mi
from
Philadelphia, PA
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
Arthritis Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
The Arthritis Clinic
mi
from
Jackson, TN
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
The Arthritis Clinic
mi
from
Jackson, TN
Click here to add this to my saved trials
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
Walter F. Chase
mi
from
Austin, TX
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
Walter F. Chase
mi
from
Austin, TX
Click here to add this to my saved trials
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
Tacoma Center for Arthritis Research, PS
mi
from
Tacoma, WA
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
Tacoma Center for Arthritis Research, PS
mi
from
Tacoma, WA
Click here to add this to my saved trials
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Capital Federal,
PoC in Rheumatoid Arthritis With Methotrexate
A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Glendale, AZ
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Mesa, AZ
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Peoria, AZ
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Phoenix, AZ
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
El Cajon, CA
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Lakewood, CA
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Lakewood, CA
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Palm Desert, CA
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Palm Desert, CA
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Tustin, CA
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Tustin, CA
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Upland, CA
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Boulder, CO
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Boulder, CO
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Trumbull, CT
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Trumbull, CT
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Lewes, DE
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Lewes, DE
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Boynton Beach, FL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Naples, FL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Orlando, FL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Palm Harbor, FL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Plantation, FL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Tampa, FL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Venice, FL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Venice, FL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Vernon Hills, IL
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Vernon Hills, IL
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Indianapolis, IN
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Cumberland, MD
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Cumberland, MD
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Lansing, MI
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Flowood, MS
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Flowood, MS
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
St Louis, MO
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Freehold, NJ
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Toms River, NJ
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Albuquerque, NM
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Hartsdale, NY
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Hartsdale, NY
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Middleburg Heights, OH
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Tulsa, OK
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Portland, OR
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Duncansville, PA
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Wyomissing, PA
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Jackson, TN
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Grapevine, TX
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Grapevine, TX
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Houston, TX
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Lubbock, TX
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated:  9/24/2015
Clinical Research Facility
mi
from
Nassau Bay, TX
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Randomized, Double-Blind, Active-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs
Status: Enrolling
Updated: 9/24/2015
Clinical Research Facility
mi
from
Nassau Bay, TX
Click here to add this to my saved trials